Reason for request

Assessment of IAB level in chronic lymphocytic leukaemia.


Clinical Benefit


The actual benefit remains substantial.

Clinical Added Value


CHLORAMINOPHENE provides a moderate improvement in actual benefit (IAB III) in terms of tolerability in the first-line treatment strategy for chronic lymphocytic leukaemia in a limited population comprising patients aged over 65 years and/or with comorbidities that make it difficult or impossible to use fludarabine on its own or in a combination regimen.

Contact Us

Évaluation des médicaments

See also